Study of CU06-1004 in Patients With Daibetic Macular Edema

Summary

This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 24 weeks. The study will have a 1:1:1 randomization (CU06-1004 200mg: CU06-1004 300mg: Placebo).

Timeline

Start

2026-12-01

Primary completion

2028-01-01

Completion

2028-01-30

Drugs

Indications